By Duncan MboyahThe World Health Organization (WHO) has endorsed a new leishmaniasis regimen with less side effects for the management of the disease in Eastern Africa. Dr. Daniel Ngamije Madandi, WHO director of Malaria and Neglected Tropical Diseases (NTDs) said that for too long, patients suffering from leishmaniasis have endured treatments nearly as punishing as the disease itself. “We are delighted that more patient-friendly treatments developed with our partners have been included in the WHO guidelines,” he added. Dr. Alves said partners are now working on the development of a promising new oral candidate that could help soon finally move away from injectable regimens. These new therapies recommended for Eastern Africa were developed by the non-profit medical research organization Drugs for DNDi and partners.